Melanoma is notorious for its high likelihood to spread to the brain, leading to significant challenges in treatment and poor survival rates for affected patients. Understanding the interactions between tumor cells and the brain microenvironment is crucial for developing effective therapeutic strategies. In a recent study, researchers investigated the role of extracellular vesicle (EV)-derived miR-146a-5p in promoting the progression of melanoma brain metastasis (MBM) by modulating the brain metastatic niche.
The study revealed that miR-146a-5p was highly expressed in EVs from human MBM cell lines and patient biopsies. Mechanistically, miR-146a-5p was transferred to astrocytes via EVs, where it inhibited NUMB in the Notch signaling pathway, leading to the activation of tumor-promoting cytokines. Knockdown of miR-146a-5p resulted in a significant reduction in brain metastases, highlighting its pro-metastatic role. Furthermore, molecular docking analysis identified deserpidine as a functional inhibitor of miR-146a-5p, showing promise for targeted adjuvant therapy.
The brain microenvironment plays a crucial role in supporting metastatic growth, with astrocytes being key players in this process. The study demonstrated that MBM-EVs induced activation and altered cytokine production in normal human astrocytes (NHAs). This activation was mediated by miR-146a-5p, which was found to be significantly upregulated in MBM-EVs compared to normal cell-derived EVs. Inhibiting miR-146a-5p reduced the stimulatory effects of MBM-EVs on NHAs, pointing to its role in promoting astrocyte activation.
Further investigations delved into the downstream effects of miR-146a-5p on NHAs, revealing its impact on the Notch signaling pathway through downregulation of NUMB expression. The study identified NUMB as a direct target of miR-146a-5p, leading to increased Notch pathway activation and subsequent cytokine production. Inhibition of Notch signaling reversed the effects of miR-146a-5p on astrocyte activation and cytokine expression, underscoring the intricate regulatory network involved in MBM progression.
A key finding of the study was the successful knockdown of miR-146a-5p in MBM cells, resulting in decreased tumor burden and improved survival in a mouse model of brain metastasis. Mice injected with miR-146a-5p knockdown cells exhibited significantly reduced MBM burden and prolonged survival compared to control animals. Additionally, the knockdown tumors showed lower proliferation rates, as indicated by reduced Ki67 expression, emphasizing the therapeutic potential of targeting miR-146a-5p in mitigating MBM progression.
This comprehensive investigation sheds light on the intricate mechanisms underlying the role of miR-146a-5p in promoting MBM progression through astrocyte activation and Notch pathway dysregulation. Targeting miR-146a-5p or its downstream pathways presents a promising avenue for developing novel therapeutic interventions to combat melanoma brain metastasis and improve patient outcomes. The identification of deserpidine as a functional inhibitor of miR-146a-5p further highlights the translational potential of these findings for future clinical applications.
Tags: immune checkpoint inhibitors, virtual screening, molecular docking, downstream, liquid biopsy, secretion, lentiviral vectors, cell culture, validation, transduction
Read more on pmc.ncbi.nlm.nih.gov